Skip to main content
Premium Trial:

Request an Annual Quote

Mix 'Em Together

Moderna is planning to have a combination SARS-CoV-2, influenza, and RSV vaccine by the 2023 flu season, the Guardian reports.

The company began testing an mRNA-based vaccine for seasonal influenza in July 2021. That vaccine, it said at the time, was targeting the influenza A H1N1 and H3N2 lineages and the influenza B Yamagata and Victoria lineages. Moderna added, according to Ars Technica, that it hoped to potentially combine that vaccine with vaccines for RSV, human metapneumovirus, and, possibly, SARS-CoV-2.

According to the Guardian, Moderna CEO Stéphane Bancel said during a panel session of the World Economic Forum in Davos that a combination vaccine would help with compliance, as people would only need one shot, rather than multiple shots. Politico Europe adds that the flu vaccine should enter into phase three testing in the second quarter of the year.

Bancel further announced that the company's Omicron-specific booster is still under development but should enter clinical testing soon and should have data for regulatory authorities in March.

Ars Technica notes that Pfizer said last week that its Omicron-specific booster should also be ready in March.